Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases

Table 2

Results of hepatotoxicity and treatment with gefitinib and erlotinib.

Case	Worst grade of gefitinib-induced hepatotoxicity	Peak AST/ALT levels by gefitinib-induced hepatotoxicity (mg/dL)	Time to gefitinib-induced hepatotoxicity (days)	Response by gefitinib	Duration of treatment with gefitinib (days)	Retreatment with gefitinib	Initial dose of erlotinib (mg)	Worst grade of erlotinib-induced hepatotoxicity	Peak AST/ALT levels by erlotinib-induced hepatotoxicity (mg/dL)	Response by erlotinib	Duration of treatment with erlotinib (days)
1	2	63/155	22	PR	47	decreased^a	100	2	46/85	PR	159
2	3	159/280	175	PR	189	decreased^a	150	0	22/21	SD	92
3	2	128/197	42	PR	42	no	100	0	23/31	SD	184
4	3	89/263	53	PR	204	decreased^a	100	1	70/62	SD	116
5	3	426/533	55	PR	167	decreased^a	100	1	71/45	SD	360
6	3	252/252	191	PR	191	no	100	0	17/28	SD	56
7	3	231/342	35	PR	58	decreased^a	75	0	18/22	PR	304
8	2	62/113	50	SD	50	no	75	0	23/30	SD	412

Abbreviations: AST: aspartate aminotransferase; ALT: alanine aminotransferase; PR: partial response; SD: stable disease.
^aRetreatment with decreased amount of gefitinib.